Oligonucleotides’ ability to inhibit genes or to function as aptamers to interact with protein targets are increasingly vital research tools in the biopharmaceutical industry. Oligonucleotides target RNA at the cellular level, where
specific malfunctioning genes can be manipulated and/ or modulated. Anjali Alving of Bruker Scientific discusses  how this capability presents biopharma companies with opportunities to target diseases which have proven difficult to combat using classic small molecule approaches.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/07/Mass-Spectrometry-Supports-Development-of-New.pdf”]